Theravance Biopharma, Inc.: insider trades · United States · SEC (Form 4)

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker TBPH. Operationally, the company is split between South San Francisco, California, in the United States, and Dublin, Ireland. It became an independent publicly traded company on June 2, 2014, following its separation from Theravance, Inc. The company’s mission is to develop and commercialize differentiated medicines, with a particular emphasis on specialty respiratory disease. ([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-inc-and-theravance-biopharma-inc-announce-completion?utm_source=openai)) Theravance Biopharma’s business model has gradually shifted from a broad research-and-development biotech toward a more focused company centered on a streamlined portfolio. Its commercial anchor is YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease (COPD). The company highlights decades of respiratory-disease expertise and positions itself around “medicines that make a difference,” with value creation coming from both a marketed product and selective pipeline optionality. ([theravance.com](https://www.theravance.com/about-us/our-company/?utm_source=openai)) In competitive terms, TBPH is best viewed as a specialized small/mid-cap biotech rather than a diversified pharma platform. That specialization allows management to concentrate capital and operating attention on a narrow set of therapeutic opportunities where it believes it can build durable value. The company also relies on collaboration structures and shared commercialization economics, particularly for YUPELRI in the U.S. with Viatris, which reduces the burden of building a fully integrated sales organization from scratch. ([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-third-quarter-2025-financial?utm_source=openai)) Recent developments have been especially important for the investment case. In March 2026, Theravance Biopharma reported fourth-quarter and full-year 2025 results, citing another record quarter of non-GAAP profitability, record brand-level profitability for YUPELRI, and a strengthened balance sheet. At the same time, the company’s ampreloxetine program became the key clinical catalyst: enrollment in the pivotal CYPRESS Phase 3 study was completed in 2025, but topline results announced in March 2026 showed the study did not meet its primary endpoint. Following that outcome, the board accelerated its strategic review and the company announced cost-reduction measures. Management has signaled a sharper focus on maximizing value from YUPELRI and preserving financial flexibility. ([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-8?utm_source=openai)) For investors, Theravance Biopharma remains a specialized healthcare name on the NASDAQ in the United States, combining a commercial respiratory asset with residual pipeline and strategic-review optionality. The stock’s profile reflects both biotech execution risk and the potential for value realization through disciplined capital allocation and corporate actions.